Skip to Main content Skip to Navigation
Journal articles

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)

Abstract : Postmenopausal women with large, hormone receptor (HR)-positive/HER2-negative and low-proliferative breast cancer derived a benefit from neoadjuvant endocrine therapy (NET) in the CARMINA02 trial. This study was designed to correlate gene expression and mutation profiles with both response to NET and prognosis.
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-01930042
Contributor : Mouniati Colo <>
Submitted on : Wednesday, November 21, 2018 - 3:23:17 PM
Last modification on : Wednesday, May 27, 2020 - 6:48:01 AM

Links full text

Identifiers

Citation

Xu Liang, Adrien Briaux, Véronique Becette, Camille Benoist, Anais Boulai, et al.. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609). Journal of Hematology and Oncology, BioMed Central, 2018, 11 (1), pp.124. ⟨10.1186/s13045-018-0670-9⟩. ⟨hal-01930042⟩

Share

Metrics

Record views

105